Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

IDL Diagnostics

0.35 SEK

-0.85 %

Less than 1K followers

IDLDX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-0.85 %
-0.85 %
-1.13 %
-8.64 %
-22.10 %
-30.89 %
-53.90 %
-89.66 %
-85.35 %

IDL Diagnostics specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. IDL Diagnostics targets patient groups in different parts of the world. The head office is in Stockholm.

Read more
Market cap
80.4M SEK
Turnover
28.52K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.5.
2026

Interim report Q1'26

28.5.
2026

General meeting '26

20.8.
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Arocell’s Q2 released. https://storage.mfn.se/714276aa-5dee-4a93-9c7b-ee487abb1821/arocell-interim-report-q2-2024.pdf The result is safely in the red, but a new record was set in terms of revenue, and regarding cash flow, I believe the first positive quarter in at least the history...
8/21/2024, 6:50 AM
by Kultapossu
10
And today, the Chinese patent approval apparently came through
2/14/2025, 8:44 AM
by Arsene
9
Arocell’s Q4 report published. I quickly entered the figures into Excel, and it seems to be heading in a better direction. All in all, a pretty good quarter: best ever in terms of revenue, the first EBITDA-positive, and already the second positive quarter in terms of cash flow (last...
2/19/2025, 7:13 AM
by Kultapossu
7
The direction is clearly correct. This * Includes costs for goodwill amortization of KSEK 39,578 (39,578) for the period.* is puzzling, the result would be impressively positive, but that annual “amortization” still lurks in the figures, what on earth is it?
2/19/2025, 7:22 AM
by Arsene
4
Is something finally happening with Arocell, I wonder? In Redeye’s report IDL Diagnostics - Redeye, the “Momentum” section has now risen from 2 to 4 in a short period of time. The scale is 1-5, and it had been at 2 for quite a long time before this. On Placera’s forum Placera Forum...
2/14/2025, 6:39 AM
by Arsene
4
Behind the link is also RE’s view of the quarter. They are hinting at a new urology-related acquisition. https://www.redeye.se/api/articles/download-file/c11b73c7-abef-3b6b-9d08-a8b87ffadd0f/AroCell%20Q2%3A%20First%20quarter%20with%20a%20positive%20cash%20flow
8/22/2024, 6:04 AM
by Kultapossu
3
IDL Diagnostics Article - IDL Diagnostics [et_pb_section fb_built=”1″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4...
11/10/2025, 11:04 AM
by N00B
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.